Mi-Helper, Inc.

I’m attending #AANAM April 5 – 9. Will you be joining me and esteemed author Dr. MaryAnne Mays from the Cleveland Clinical to see hear about the “Mi-Helper Transnasal Cooling for Acute Migraine Treatment: A Prospective, Double-blind, Randomized, Sham-controlled, Decentralized Dosing Study” data including the oral presentation on April 7 at 11:45am. I can’t wait to see you in San Diego! @AANmember/@AANbrain #Migraine #neuromodulation #medtech

Why am I elated? Yesterday Mi-Helper, Inc. completed it's final closing of an oversubscribed $10M Series A Financing. Relief is on the way!!

Mi-Helper successfully secured commitments for a a Series A extension, bolstering their total Series A funding to $10M with an additional $1.6M. This milestone comes on the heels of superb results from a recent nationwide randomized controlled trial. Oversubscription will not be allowed, however a waiting list has been formed for future investment opportunities. We are grateful to our existing and new investors supporting us on our journey to provide a drug-free, affordable, effective, and convenient solution to end migraine attacks. #Healthcare #Innovation #MigraineSolution #Migraine #Medicaldevice #medtech

Mi-Helper successfully secured commitments for a a Series A extension, bolstering their total Series A funding to $10M with an additional $1.6M. This milestone comes on the heels of superb results from a recent nationwide randomized controlled trial. Oversubscription will not be allowed, however a waiting list has been formed for future investment opportunities. We are grateful to our existing and new investors supporting us on our journey to provide a drug-free, affordable, effective, and convenient solution to end migraine attacks. #Healthcare #Innovation #MigraineSolution #Migraine #Medicaldevice #medtech

This picture has nothing to do with me attending HLTH 2024 in Vegas. But it made you look. I will be there and talking about the phenomenal Mi-Helper drug free home therapy for migraine and much more. Ask me about the limited extension to the oversubscribed Series A Preferred investment opportunity. Hope to see you there!!!

Two significant announcements from Mi-Helper, Inc.! 1) Our recent double-blinded, randomized controlled study revealed statistically significant pain freedom within two hours compared to sham. Study subjects, who self-administered the 15-minute therapy at home, remained pain-free at 24 hours. Stay tuned for the full publication of results. 2) Building on these promising findings, Mi-Helper is increasing the Series A Preferred financing by $1.6M. This extension will also qualify for an Opportunity Zone Level Biotech Incentive Tax Credit, offering a $1.2M cash benefit to participating investors. Exciting developments ahead for Mi-Helper! #Healthcare #Biotech #Innovation #medtech

Mi-Helper has successfully completed a groundbreaking clinical study to address episodic migraine, involving 172 individuals nationwide. This innovative therapy offers a simple, safe, and drug-free solution, completed in just 15 minutes from the comfort of one's home. Stay tuned for study results for this promising new therapy. Please note that this product is currently intended for investigational use only. #ClinicalStudy #MigraineTreatment #HealthcareInnovation #medtech